South Korean pharmaceutical companies entered into 11 out-licensing deals with overseas partners in 2018, according to the country’s Ministry of Health and Welfare.
India-based drug company Sun Pharma has made further inroads into the Japanese market with the planned acquisition of Pola Pharma.
Scientists have urged policymakers to implement a regulatory framework governing the use of CRISPR technology in humans, following reports that a Chinese scientist has successfully created ‘edited’ twins.
The Delhi High Court has ruled against a company for its ‘near identical’ imitation of pharmaceutical company Sanofi’s name and trademarks.
Last year, for the first time in European Patent Office history, a Chinese company filed the most European patent applications, making an “impressive statement” on what companies in the country are doing, according to Peter Albrecht.
The Australian Competition & Consumer Commission announced yesterday that it has approved the merger of generic drugs companies Arrow and Apotex.
The Bombay High Court has imposed Rs 1.5 crore of costs on a pharmaceutical company which infringed India-based Glenmark Pharmaceuticals’ trademarks.
York Faulkner, an IP partner from Finnegan, Henderson, Farabow, Garrett & Dunner, has joined Quinn Emanuel Urquhart & Sullivan in Tokyo.
Japan-based Astellas Pharma has acquired Quethera, a UK-headquartered gene therapy company focused on developing treatments for ocular disorders.
South Korea-based Samsung has revealed plans to commit W25 trillion to pursue new technology in areas including biopharmaceuticals and artificial intelligence.